eFigure 1. Sampling Procedure for the Case-Cohort Subsample.
Of 42,558 non-Hispanic White women enrolled in the Sister Study, 1,336 were randomly sampled from the full cohort. Of these women, 91 developed breast cancer (15 ductal carcinoma in situ [DCIS] and 76 invasive) by October 2016. The random subsample was supplemented with an additional 1,540 cases (324 DCIS and 1,216 invasive) that developed cancer by October 2016. In total, 2,876 women were selected for blood genome-wide DNA methylation assessment. Of the 2,876 assays, 102 failed quality control: 91 samples that had average bisulfite intensity < 4000 or had more than 5% of probes with low-quality methylation values (detection p >0.000001, number of beads <3, or values outside of 3IQR); 4 samples that were outliers for their methylation beta value distributions; 1 sample with missing phenotype data; and 6 women whose date of diagnosis preceded blood draw. After quality control, 1,204 non-cases and 1,569 cases remained for analysis (conducted in April 2019).
eFigure 3. Leukocyte Proportion Estimates Over Time
Leukocyte subtypes estimated among an independent sample of cancer-free women (n= 8) with three blood draws over a one-year period, approximately five months apart. Each line color represents an individual (consistent across cell types). Genome-wide DNA methylation was assessed using an older methylation array (Infinium HumanMethylaiton27 BeadChip) and CD4+ and CD8+ T-cells were combined. 
